March 28, 2002

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832


ZOLL Medical Addresses Patent Infringement Allegations

BURLINGTON, MA  Thursday, March 28, 2002 – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, today commented on a press release by Cardiac Science, Inc. stating it had filed suit alleging infringement on two patents by ZOLL Medical Corporation.

Richard A. Packer, President and Chief Executive Officer of ZOLL stated, “With respect to the patents in question, ZOLL is confident that the AED Plus does not infringe these patents. We received a copy of the complaint this afternoon and we do not believe the allegations in the complaint have any more merit than those in the press release.”

Mr. Packer added, “ZOLL is the major product innovator in our industry and we protect our product innovations very carefully. When we develop new products, we respect the intellectual property of other companies. We use a highly respected, national intellectual property firm to facilitate our efforts.” He concluded, “We are confident in our non-infringement position. We will use all our corporate resources to defend against such improper allegations of infringement.”

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software that automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands, and Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit the ZOLL web site at

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the intent, belief or current expectations of the Company, its directors or its officers, primarily with respect to the Company's business model and future operating performance of the Company, including expectations regarding results in future periods, operating performance, contributions to results from the Company’s new Public Access Defibrillation product, the payoff that may be realized from investments and the Company’s future profitability, its ability to establish a new sales force in foreign markets, its expectations regarding future purchasing activity, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-Q filed on February 13, 2002, as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus and M Series CCT, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital market, the potential disruption in the transportation industry on the Company’s supply chain and product distribution channels, and the desire or ability of other parties to purchase the Company's products.

# # #